FENNEC PHARMACEUTICALS INC. 8-K

What Happened
Fennec Pharmaceuticals Inc. filed an 8‑K reporting the results of its annual meeting of shareholders held on June 10, 2026. All five director nominees were elected, Haskell & White LLP was appointed as independent auditors, the advisory “say-on-pay” and advisory frequency votes were passed, and amendments to the 2020 Equity Incentive Plan and a new 2026 Equity Inducement Plan were approved.

Key Details

• Directors elected (each to serve until the next annual meeting):
  • Dr. Khalid Islam — For: 20,246,596; Withheld: 126,891; Broker Non‑Votes: 5,881,885
  • Chris A. Rallis — For: 20,126,058; Withheld: 247,429; Broker Non‑Votes: 5,881,885
  • Marco Brughera — For: 20,237,230; Withheld: 136,257; Broker Non‑Votes: 5,881,885
  • Jodi Cook — For: 20,191,538; Withheld: 181,949; Broker Non‑Votes: 5,881,885
  • Jeffrey Hackman — For: 20,282,707; Withheld: 90,780; Broker Non‑Votes: 5,881,885
• Auditor appointment: Haskell & White LLP approved as independent public accountants — For: 26,091,716; Withheld: 134,491; Against: 29,165; Broker Non‑Votes: 0.
• Advisory votes on executive compensation:
  • Say‑on‑pay (advisory): For: 19,326,750; Against: 336,060; Abstentions: 710,677; Broker Non‑Votes: 5,881,885.
  • Frequency vote (how often advisory votes should occur): For “Every One Year”: 18,235,648; Every Two Years: 2,326; Every Three Years: 2,086,219; Abstentions: 49,294.
• Equity plans:
  • Amendments to 2020 Equity Incentive Plan approved — For: 17,425,439 (note: 766,153 shares held by officers/directors were deducted from the For vote); Against: 1,429,951; Abstentions: 751,944; Broker Non‑Votes: 5,881,885.
  • 2026 Equity Inducement Plan ratified — For: 18,626,207; Against: 1,033,779; Abstentions: 713,501; Broker Non‑Votes: 5,881,885.

Why It Matters
These votes confirm the board composition and give management shareholder approval for key governance items: the independent auditor, executive pay approach (advisory), the timing of future advisory votes, and equity compensation frameworks (2020 plan amendments and a new 2026 inducement plan). For investors, these outcomes affect governance oversight, potential dilution from equity awards, and the company’s compensation practices—factors that can influence corporate strategy and shareholder value over time.